Advertisement

In-Stent Restenosis: Definition, Entity of the Problem, Etiopathogenesis and Treatment Options

  • Davide Piraino
  • Giuliana Cimino
  • Dario Buccheri
  • Giuseppe Andolina
Chapter

Abstract

In-stent restenosis (ISR) still represents a frequent limitation of percutaneous coronary intervention despite the introduction of latest-generation drug-eluting stents (DES), drastically lowering the overall incidence of ISR. Thus, the treatment of DES ISR remains a real brainteaser for interventional cardiologists.

Neointimal hyperplasia and neoatherosclerosis are the two main causes of ISR. Understanding of the underlying mechanism(s) appears critical to treat ISR optimally using the available options such as the latest-generation DES, drug-coated balloons (DCB), or bioresorbable scaffolds (BRS).

References

  1. 1.
    Eeckhout E, Serruys PW, Wijns W, Vahanian A, Van Sambeek M. In: Percutaneous Interventional Cardiovascular Medicine: the PCR–EAPCI Textbook, Europa Ed, 2012: p785–826.Google Scholar
  2. 2.
    Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Interv. 2015;8:1586–94.CrossRefGoogle Scholar
  4. 4.
    Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug eluting stent comparison. Circulation. 2005;111:3435–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, David Fish R, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501.CrossRefPubMedGoogle Scholar
  6. 6.
    Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, JV T, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198–206.CrossRefPubMedGoogle Scholar
  7. 7.
    Cortese B, Berti S, Biondi Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia GA, Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014;83:427–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012;161:4–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Le Feuvre C, Bonan R, Lespérance J, Gosselin G, Joyal M, Crépeau J. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty. Am J Cardiol. 1994;73:840–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Agostoni P, Valgimigli M, Biondi-Zoccai GG, Abbate A, Garcia Garcia HM, Anselmi M, Turri M, McFadden EP, Vassanelli C, Serruys PW, Colombo A. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J. 2006;151:682–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K, Kaitani K, Inoue K, Nakagawa Y, Yokoi H, Iwabuchi M, Hamasaki N, Nosaka H, Nobuyoshi M. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002;105:2986–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, Investigators SIRIUS. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Danzi GB, Piccolo R, Galasso G, Piscione F. Nobori biolimus-eluting stent vs. permanent polymer drug-eluting stents in patients undergoing percutaneous coronary intervention. Circ J. 2014;78:1858–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Steinberg DH, Mishra S, Javaid A, Slottow TL, Buch AN, Roy P, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (≥3.5 mm) coronary arteries. Am J Cardiol. 2007;99:599–602.CrossRefPubMedGoogle Scholar
  17. 17.
    Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry. J Interv Cardiol. 2013;26:153–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Sherr CJ, Roberts JMCDK. Inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Piek JJ, van der Wal AC, Meuwissen M, Koch KT, Chamuleau SA, Teeling P, van der Loos CM, Becker AE. Plaque inflammation in restenotic coronary lesions of patients with stable or unstable angina. J Am Coll Cardiol. 2000;35:963–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001;21:1152–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention. 2008;4(Suppl. C):C7–10.PubMedGoogle Scholar
  26. 26.
    Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European Evaluation of Paclitaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109:487–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Kaluza GL, Gershlick AH, Park SJ, De Scheerder I, Chevalier B, Camenzind E, et al. Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials). Am J Cardiol. 2004;94:199–201.CrossRefPubMedGoogle Scholar
  28. 28.
    John MC, Wessely R, Kastrati A, Schomig A, Joner M, Uchihashi M, et al. Differential healing responses in polymer- and nonpolymer-based sirolimus eluting stents. JACC Interv. 2008;1:535–44.CrossRefGoogle Scholar
  29. 29.
    Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep. 2003;5:308–16.CrossRefPubMedGoogle Scholar
  31. 31.
    Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation. 2002;105:2986–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Habara M, Terashima M, Nasu M, Kaneda H, Inoue K, Ito T, Kamikawa S, Kurita T, Tanaka N, Kimura M, Kinoshita Y, Tsuchikane E, Matsuo H, Ueno K, Katoh O, Suzuki T. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation an optical coherence tomography study. Circ Cardiovasc Interv. 2011;4:232–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Hasegawa K, Tamai H, Kyo E, Kosuga K, Ikeguchi S, Hata T, Okada M, Fujita S, Tsuji T, Takeda S, Fukuhara R, Kikuta Y, Motohara S, Ono K, Takeuchi E. Histopathological findings of new in-stent lesions developed beyond five years. Catheter Cardiovasc Interv. 2006;68:554–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Kim JS, Lee JH, Shin DH, Kim BK, Ko YG, Choi D, Jang Y. Hong. Long-term outcomes of neointimal hyperplasia without neoatherosclerosis after drug-eluting stent implantation. JACC Img. 2014;7:788–95.CrossRefGoogle Scholar
  37. 37.
    Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–22.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ali ZA, Roleder T, Narula J, Mohanty BD, Baber U, Kovacic JC, Mintz GS, Otsuka F, Pan S, Virmani R, Sharma SK, Moreno P, Kini AS. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013;6:507–17.CrossRefPubMedGoogle Scholar
  39. 39.
    Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis. JACC. 2012;59:2051–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuramitsu S, Shirai S, Ando K. Mechanism of in-stent restenosis after second-generation drug-eluting stents (DES): is it different from bare-metal stents and first-generation DES? J Thorac Dis. 2015;7:E599–602.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhao LP, WT X, Wang L, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis. 2015;26:5–10.CrossRefPubMedGoogle Scholar
  42. 42.
    Komatsu T, Yaguchi I, Komatsu S, Nakahara S, Kobayashi S, Sakai Y, Taguchi I. Impact of insulin resistence on neointimal tissue proliferation after 2nd-generation drug-eluting stent implantation. Tex heart Inst. J. 2015;42:327–32.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Golukhova EZ, Grigorian MV, Ryabinina MN, Bulaeva NI, Fortmann S, Serebruany VL. Independent predictors of major adverse events following coronary stenting over 28 months of follow up. Cardiology. 2015;132:176–81.CrossRefPubMedGoogle Scholar
  44. 44.
    Low Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004;53:2735–40.CrossRefGoogle Scholar
  45. 45.
    Kibos A, Campeanu A, Tintoiu I. Pathophysiology of coronary artery restenosis. Acute Card Care. 2007;9:111–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Tocci G, Barbato E, Coluccia R, Modestino A, Pagliaro B, Mastromarino V, Giovannelli F, Berni A, Volpe M. Blood pressure at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am J Ipert. 2016;29:509–18.Google Scholar
  47. 47.
    Park SH, Rha SW, Choi BG, Park JY, Jeon W, Seo HS, Kim EJ, JO NA, Choi CU, Kim JW, Lim HE, Park CG, Oh DJ. Impact of high lipoprotein(a) levels on in-stent restenosis and long term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stent in Asian population. Clin Exp Pharmacol Physiol. 2015;42:588–95.CrossRefPubMedGoogle Scholar
  48. 48.
    Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3:1–19.CrossRefPubMedGoogle Scholar
  49. 49.
    Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378–91.CrossRefPubMedGoogle Scholar
  50. 50.
    Alfonso F, Cequier A, Angel J, Martí V, Zueco J, Bethencourt A, et al. Restenosis Intra-stent Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon Angioplasty Versus Elective Stenting (RIBS) randomized trial. Am Heart J. 2006;151:681.e1–9.CrossRefGoogle Scholar
  51. 51.
    Karalis I, Ahmed TAHN, Jukema JW. Late acquired stent malapposition: why, when and how to handle? Heart. 2012;98:1529–36.CrossRefPubMedGoogle Scholar
  52. 52.
    Mintz GS. What to do about late incomplete stent apposition? Circulation. 2007;115:2379–81.CrossRefPubMedGoogle Scholar
  53. 53.
    Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–34.CrossRefPubMedGoogle Scholar
  54. 54.
    Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol. 2004;43:1959–63.CrossRefPubMedGoogle Scholar
  55. 55.
    Prati F, Guagliumi G, Mintz GS, et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur Heart J. 2012;33:2513–20.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Maehara A, Ben-Yehuda O, Ali Z, Wijns W, Bezerra HG, Shite J, Généreux P, Nichols M, Jenkins P, Witzenbichler B, Mintz GS, Stone GW. Comparison of stent expansion guided by optical coherence tomography versus intravascular ultrasound the ILUMIEN II study (observational study of optical coherence tomography [OCT] in patients undergoing fractional flow reserve [FFR] and percutaneous coronary intervention). JACC Interv. 2015;8:1704–14.CrossRefGoogle Scholar
  57. 57.
    Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, Kim YH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:1305–10.CrossRefPubMedGoogle Scholar
  58. 58.
    Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, Stone GW. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent trials. JACC Cardiovasc Interv. 2009;2:1269–75.CrossRefPubMedGoogle Scholar
  59. 59.
    Song HG, Kang SJ, Ahn JM, Kim WJ, Lee JY, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation. Cathet Card Interv. 2015;83:873–8.CrossRefGoogle Scholar
  60. 60.
    Matsuo Y, Kubo T, Aoki H, Satogami K, Ino Y, Kitabata H, Taruya A, Nishiguchi T, Teraguchi I, Shimamura K, Shiono Y, Orii M, Yamano T, Tanimoto T, Yamaguchi T, Hirata K, Tanaka A, Akasaka T. Optimal threshold of postintervention minimum stent. Cathet Card Interv. 2016;87:E9–E14.CrossRefGoogle Scholar
  61. 61.
    Kang SJ, Mintz GS, Park DW, Lee SW, Kim YH, Lee CW, Han KH, Kim JJ, Park SW, Park SJ. Mechanisms of in-stent restenosis after drug eluting stent implantation. Intravascular ultrasound analysis. Circ Card Interv. 2011;4:9–14.CrossRefGoogle Scholar
  62. 62.
    Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254–65.CrossRefPubMedGoogle Scholar
  63. 63.
    Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165–71.CrossRefPubMedGoogle Scholar
  64. 64.
    Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A. Randomized trial of paclitaxel- vs. sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010;55:2710–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabate M, Escaned J, Moreno R, Banuelos C, Suarez A, Macaya CA. Randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty vs. Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47:2152–60.CrossRefPubMedGoogle Scholar
  66. 66.
    Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, Lopez-Minguez JR, Angel J, Auge JM, Gomez-Recio M, Moris C, Seabra-Gomes R, Perez-Vizcayno MJ, Macaya CA. Randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42:796–805.CrossRefPubMedGoogle Scholar
  67. 67.
    Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, Schomig A. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:616–23.CrossRefPubMedGoogle Scholar
  68. 68.
    Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8:E1150–62.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, et al. RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 2012;5:728–37.CrossRefPubMedGoogle Scholar
  70. 70.
    Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Speck U, Bohm M, Cremers B. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardi- ovasc Interv. 2012;5(3):323–30.CrossRefGoogle Scholar
  71. 71.
    Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon cath- eter. N Engl J Med. 2006;355:2113–24.CrossRefPubMedGoogle Scholar
  72. 72.
    Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter vs. paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986–94.CrossRefPubMedGoogle Scholar
  73. 73.
    Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S, von Cranach M, Nguyen TV, Daniel WG, Wohrle J. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012;59:1377–82.CrossRefPubMedGoogle Scholar
  74. 74.
    Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N, Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D, Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H, Miyake K, Yoshino M. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Interv. 2011;4:149–54.CrossRefGoogle Scholar
  75. 75.
    Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S, Kastrati A. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381:461–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, Meier P. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99:327–33.CrossRefPubMedGoogle Scholar
  77. 77.
    Piraino D, Buccheri D, Cortese B. Paclitaxel-coated balloon exerts late vessel healing and enlargement: a documented phenomenon with optical coherence tomography analysis. Int J Card. 2016;203:551–2.CrossRefGoogle Scholar
  78. 78.
    Piraino D, Cortese B, Buccheri D, Dendramis G, Andolina G. Healing after coronary artery dissection: the effect of a drug coated balloon angioplasty in a bifurcation lesion. A lesson from intravascular ultrasound analysis. Intern J Card. 2016;203:298–300.CrossRefGoogle Scholar
  79. 79.
    Cortese B, Buccheri D, Piraino D, Silva-Orrego P. Drug-coated balloon without stent implantation for chronic total occlusion of coronary arteries: description of a new strategy with an optical coherence tomography assistance. Int J Card. 2015;191:75–6.CrossRefGoogle Scholar
  80. 80.
    Piraino D, Buccheri D, Andolina G. Coronary bifurcation lesions: some questions need an answer to make bioresorbable vascular scaffold technology more “coronary bifurcation-friendly”. Int J Card. 2016;215:80–3.CrossRefGoogle Scholar
  81. 81.
    Cortese B, Silva-Orrego P, Agostoni P, Buccheri D, Piraino D, Andolina G, Seregni RG. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Intv. 2015;8:2003–9.CrossRefGoogle Scholar
  82. 82.
    Cortese B, Piraino D, Galfrascoli E, Silva-Orrego P. Left main stem angioplasty without metal: a new paradigm in interventional cardiology? EuroIntervention. 2016;12:759.CrossRefPubMedGoogle Scholar
  83. 83.
    Cortese B, Piraino D, Buccheri D, Alfonso F. Treatment of bifurcation lesions with drug-coated balloons: a review of currently available scientific data. Int J Card. 2016;220:589–94.CrossRefGoogle Scholar
  84. 84.
    Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5:392–400.CrossRefPubMedGoogle Scholar
  85. 85.
    Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. J Am Coll Cardiol Intv. 2014;7:204–11.CrossRefGoogle Scholar
  86. 86.
    Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. Eurointerv. 2015;11(8):926–34.CrossRefPubMedGoogle Scholar
  87. 87.
    Lee JM, Park J, Kang J, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Intv. 2015;8:382–94.CrossRefGoogle Scholar
  88. 88.
    Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J. 2010;(31):2501–55.Google Scholar
  89. 89.
    Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;2014(35):2541–619.Google Scholar
  90. 90.
    Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V clinical trial (restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63:1378–86.CrossRefPubMedGoogle Scholar
  91. 91.
    Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015;66:23–33.CrossRefPubMedGoogle Scholar
  92. 92.
    Basavarajaiah S, Naganuma T, Latib A, Sticchi A, Cigonte G, Panoulas V, Chieffo A, Montorfano M, Carlino M, Colombo A. Treatment of drug-eluting stent restenosis: comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Catheter Cardiovasc Interv. 2016;888:522–8.CrossRefGoogle Scholar
  93. 93.
    Habara S, Kadota K, Kanazawa T, Ichinohe T, Kubo S, Hyodo Y, Otsuru S, Hasegawa D, Tada T, Tanaka H, Fuku Y, Goto T, Mitsudo K. Paclitaxel-coated balloon catheter compared with drug-eluting stent for drug-eluting stent restenosis in routine clinical practice. EuroIntervention. 2016;11:1098–105.CrossRefPubMedGoogle Scholar
  94. 94.
    Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386:655–64.CrossRefPubMedGoogle Scholar
  95. 95.
    Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han KJ, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8:382–94.CrossRefPubMedGoogle Scholar
  96. 96.
    Miglionico M, Mangiacapra F, Nusca A, Scordino D, Gallo P, Campanale M, Melfi R, Di Sciascio G. Efficacy and safety of paclitaxel-coated balloon for the treatment of in-stent restenosis in high-risk patients. Am JCardiol. 2015;116:1690e1694.CrossRefGoogle Scholar
  97. 97.
    Buccheri D, Piraino D, Andolina G, Cortese B. Drug-coated balloon for Instent restenosis in patients at high risk: another brick in the wall of the challenging settings for interventionists. Am J Card. 2016;117:1859–61.CrossRefPubMedGoogle Scholar
  98. 98.
    Cimino G, Piraino D, Buccheri D, Andolina G, Assennato P, Crea F, Trani C. Small vessel caliber in-stent restenosis in diabetic patients: drug coated balloon as treatment option in this high risk population. A two-center experience. G Ital Cardiol. 2016;17(Suppl. 2):e15.Google Scholar
  99. 99.
    Piraino D, Buccheri D, Andolina G. Recurrent in-stent restenosis: many treatment options, no certainty. EuroIntervention. 2016;11:1446–7.CrossRefPubMedGoogle Scholar
  100. 100.
    Piraino D, Buccheri D, Cimino G, Andolina G. Drug-coated balloon for recurrent in-stent restenosis treatment: a suitable strategy. Int J card. 2016;221:1084–6.CrossRefGoogle Scholar
  101. 101.
    Moscarella E, Ielasi A, Granata F, Coscarelli S, Stabile E, Latib A, Cortese B, Tespili M, Tanaka A, Capozzolo C, Caliendo L, Colombo A, Varricchio A. Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis. A multicenter Italian experience. Circ Cardiovasc Interv. 2016;9:e003148.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Davide Piraino
    • 1
  • Giuliana Cimino
    • 1
  • Dario Buccheri
    • 1
  • Giuseppe Andolina
    • 1
  1. 1.Interventional Cardiology Unit, Department of Cardiology, «P.Giaccone» Universitary Hospital of PalermoPalermoItaly

Personalised recommendations